Frequency unknown: Angioedema, back pain, cutaneous vasculitis, interstitial lung disease, joint disorders, myalgia, pancreatitis, renal impairment, StevensJohnson syndrome, hepatic function abnormalities
The absence of marketing authorisation also means that no approved UK product information defines a human dose, indication, contraindication, adverse-effect profile or monitoring programme
If its for general wellness or appearance, its not eligible
By End User: Direct consumers are forecast to hold 43.9% share in 2026 as users begin care when treatment intent is high
Patients using GLP-1 receptor agonists were also more likely to have microvascular complications and a history of depression
S3 1 H NMR spectra of a 3-PLG-dopa, b 3-PLG-ibu, c 3-PLG-dopa-A-GSH, and d 3-PLG-ibu-A-GSH